Have a feature idea you'd love to see implemented?
Let us know!
OCGN Ocugen Inc
Price (delayed)
$0.91
Market cap
$261.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.19
Enterprise value
$252.82M
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier
Highlights
Ocugen's gross profit has surged by 140% YoY and by 9% QoQ
OCGN's revenue has soared by 140% YoY and by 9% from the previous quarter
OCGN's quick ratio has dropped by 83% year-on-year and by 46% since the previous quarter
The equity has shrunk by 76% YoY and by 44% QoQ
Key stats
What are the main financial stats of OCGN
Market
Valuations
Earnings
Shares outstanding
287.86M
Market cap
$261.95M
Enterprise value
$252.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
13.83
Price to sales (P/S)
28.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.87
Revenue
$8.19M
EBIT
-$50.86M
EBITDA
-$49.24M
Free cash flow
-$54.47M
Per share
Balance sheet
Liquidity
EPS
-$0.19
Free cash flow per share
-$0.21
Book value per share
$0.07
Revenue per share
$0.03
TBVPS
$0.16
Total assets
$40.54M
Total liabilities
$23.62M
Debt
$6.87M
Equity
$16.93M
Working capital
$645,000
Debt to equity
0.41
Current ratio
1.04
Quick ratio
0.89
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
-601.2%
Gross margin
100%
Net margin
-620.9%
Operating margin
-631.3%
Return on assets
-79.2%
Return on equity
-125.5%
Return on invested capital
-332.8%
Return on capital employed
-225.3%
Return on sales
-620.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OCGN stock price
How has the Ocugen stock price performed over time
Intraday
-2.15%
1 week
-3.1%
1 month
-12.5%
1 year
127.5%
YTD
58.26%
QTD
-8.28%
Financial performance
How have Ocugen's revenue and profit performed over time
Revenue
$8.19M
Gross profit
$8.19M
Operating income
-$51.71M
Net income
-$50.86M
Gross margin
100%
Net margin
-620.9%
Ocugen's gross profit has surged by 140% YoY and by 9% QoQ
OCGN's revenue has soared by 140% YoY and by 9% from the previous quarter
The company's operating margin has surged by 77% YoY and by 20% QoQ
The net margin has soared by 76% YoY and by 20% from the previous quarter
Growth
What is Ocugen's growth rate over time
Valuation
What is Ocugen stock price valuation
P/E
N/A
P/B
13.83
P/S
28.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.87
The EPS has surged by 53% year-on-year and by 24% since the previous quarter
The price to book (P/B) is 81% more than the 5-year quarterly average of 7.8 and 32% more than the last 4 quarters average of 10.7
The equity has shrunk by 76% YoY and by 44% QoQ
OCGN's revenue has soared by 140% YoY and by 9% from the previous quarter
The price to sales (P/S) is 26% less than the last 4 quarters average of 39.5
Efficiency
How efficient is Ocugen business performance
The return on sales has surged by 76% year-on-year and by 20% since the previous quarter
The ROIC has soared by 58% YoY and by 16% from the previous quarter
OCGN's ROE is down by 10% year-on-year and by 7% since the previous quarter
The return on assets has grown by 9% year-on-year and by 5% since the previous quarter
Dividends
What is OCGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OCGN.
Financial health
How did Ocugen financials performed over time
OCGN's total assets is 72% greater than its total liabilities
OCGN's quick ratio has dropped by 83% year-on-year and by 46% since the previous quarter
The current ratio has dropped by 81% year-on-year and by 44% since the previous quarter
The debt is 59% less than the equity
The debt to equity has surged by 78% since the previous quarter
The equity has shrunk by 76% YoY and by 44% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.